
Integra LifeSciences Holdings Corporation: updates and filings
Price
$13.25
November 20, 2026Market cap $1.0B
What Ploutos Investor adds for Integra LifeSciences
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Oct 21, 2026next Jan 29, 2027
An estimate from when it has reported before, and the timing has varied a little. The company announces the date itself.
October 2026
- 23FriReportQuarterly report · for the period to Sep 30, 2026Document
- 21WedResultsResults of operationsDocument
- 19MonDealMaterial agreement entered, material agreement ended, new material financial obligation, Regulation FD disclosureDocument
- 2FriResultsResults of operations, Regulation FD disclosureDocument
July 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 10, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Oct 23, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 21, 2026Results of operationsForm8-K
- Oct 19, 2026Material agreement entered, material agreement ended, new material financial obligation, Regulation FD disclosureForm8-K
- Oct 9, 2026Regulation FD disclosureForm8-K
- Oct 2, 2026Results of operations, Regulation FD disclosureForm8-K
- Sep 8, 2026Regulation FD disclosureForm8-K
- Aug 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 31, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 29, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jul 29, 2026Results of operationsForm8-K
- May 29, 2026Conflict minerals reportFormSD
- May 15, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 8, 2026Shares registered for employeesFormS-8
- May 8, 2026Officer or director change, shareholder voteForm8-K
- May 5, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 5, 2026Additional annual meeting materialFormDEFA14A
- May 5, 2026Officer or director changeForm8-K
- May 5, 2026Results of operationsForm8-K
- Apr 15, 2026Material agreement enteredForm8-K
- Apr 6, 2026Annual meeting proxy statementFormDEF 14A
- Mar 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Feb 26, 2026Shelf registration for future offeringsFormS-3ASR
- Feb 26, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 26, 2026Results of operationsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 10, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Oct 23, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 21, 2026 | 8-K | Results of operations | Document |
| Oct 19, 2026 | 8-K | Material agreement entered, material agreement ended, new material financial obligation, Regulation FD disclosure | Document |
| Oct 9, 2026 | 8-K | Regulation FD disclosure | Document |
| Oct 2, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Sep 8, 2026 | 8-K | Regulation FD disclosure | Document |
| Aug 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 31, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 29, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jul 29, 2026 | 8-K | Results of operations | Document |
| May 29, 2026 | SD | Conflict minerals report | Document |
| May 15, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 8, 2026 | S-8 | Shares registered for employees | Document |
| May 8, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 5, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 5, 2026 | DEFA14A | Additional annual meeting material | Document |
| May 5, 2026 | 8-K | Officer or director change | Document |
| May 5, 2026 | 8-K | Results of operations | Document |
| Apr 15, 2026 | 8-K | Material agreement entered | Document |
| Apr 6, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Feb 26, 2026 | S-3ASR | Shelf registration for future offerings | Document |
| Feb 26, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 26, 2026 | 8-K | Results of operations | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Feb 14, 1996.
The full analysis
What do Integra LifeSciences's filings show?
The filings are where every one of Integra LifeSciences's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.